

**07:30** Registration & Coffee

**08:20** Opening Speech by Leonard Sachs, Managing Director, Sachs Associates Ltd.

**08:30** Keynote Speech: "Transforming Translational Neuroscience"  
by Michael D. Ehlers, Group SVP, Head, BioTherapeutics R&D, CSO, Neuroscience & Pain, Cambridge & Boston Site Head, Pfizer, Inc. (10min Q&A session)

**09:00** Deal Making  
Chaired:  
Beth Jacobs, Managing Partner, Excellentia Global Partners  
Panellists:  
Joel Braunstein, Chief Executive Officer, C2N Diagnostics  
Peter Thompson, Venture Partner, OrbiMed Advisors, LLC  
Thomas Heffner, Executive Director of Worldwide Business Development, Pfizer, Inc.

**Presenting Track A**  
Moderated by: Keay Nakae, Chardan Capital Markets, LLC

**09:35** Public Markets  
Chaired:  
Elemer Piros, Senior Biotechnology Analyst, ROTH Capital Partners  
Panellists:  
Bruce Leuchter, Managing Director, PJT Partners  
David Baker, Chief Commercial Officer, Alcobra Ltd.  
Jeffrey Davis, Chief Operating Officer, Abeona Therapeutics, Inc.  
Stephen Webster, Chief Executive Officer, Spark Therapeutics, Inc.

**09:40** neurotecnix, Inc.

**09:50** Pharmasum Therapeutics AS

**10:00** T3D Therapeutics, Inc.

**10:10** Alcyone Lifesciences, Inc.

**10:10** Keynote Speech "Reinventing the Treatment of Dementia: A New Paradigm"  
by Vivek Ramaswamy, Chief Executive Officer, Axovant Sciences, Inc.

**10:20** Cognition Therapeutics, Inc.

**10:30** Coffee Break

**10:45** Keynote Speech "New Directions for the Prevention and Reversal of Neurodegeneration"  
by Prof. Dr. Daniel Alkon, Chief Scientific Officer, Neurotrope BioScience, Inc.

**Presenting Track B**  
Moderated by: Maxim Jacobs, Edison Investment Research

**11:05** Advances in Alzheimer's Disease  
Co-Chaired:  
Kiran Reddy, Venture Partner, Clarus Ventures, LLC  
Ryan Westphal, Sr. Director, Neuroscience Search & Evaluation, Eli Lilly and Co.  
Panellists:  
Barry Kenny, Chief Business Officer, Heptares Therapeutics  
Carlos Buesa, Chief Executive Officer, Oryzon Genomics SA  
Eric Siemers, Distinguished Medical Fellow, Eli Lilly and Co.  
Hendrik Liebers, CFO, Probiodrug AG  
Jerry McLaughlin, President & CEO, AgeneBio, Inc.  
John Renger, Associate VP, Target Acceleration & Translational Capabilities, Neuroscience, Merck  
Mark Mintun, President & Chief Medical Officer, Avid Radiopharmaceuticals, Inc.  
Murali Gopalakrishnan, Senior Director, Search & Evaluation Neuroscience, AbbVie, Inc.  
Stacie Weninger, Executive Director, F-Prime Biomedical Research Initiative

**11:05** Cleveland Clinic

**11:15** Purdue Pharma L.P.

**11:35** Cerecor, Inc. - [NASDAQ:CERC]

**11:55** PsychoGenics Inc.

**12:35** Networking Lunch

NOTES:

**13:35** **Advances in Parkinson's Disease and Lewy Body Dementia**  
**Chaired:**  
 Ginger Johnson, Vice President, Defined Health  
**Panellists:**  
 Andrew Singleton, Laboratory Chief, National Institute on Aging NIH  
 Gerald Commissiong, President & CEO, Amaranthus BioScience Holdings, Inc.  
 Kees Been, Chief Executive Officer, Lysosomal Therapeutics  
 Timo Veromaa, President and CEO, Biotie Therapies Corp.  
 Todd Sherer, Chief Executive Officer, The Michael J. Fox Foundation

**Presenting Track C**  
 Moderated by: TBA

**13:35** Anelixis Therapeutics, LLC

**13:55** Vaccinex, Inc.

**14:35** **Rare & Orphan Diseases**  
**Chaired:**  
 Mark Day, Executive Director, Head of External Research & Scouting, Alexion Pharmaceuticals, Inc.  
**Panellists:**  
 Jak Knowles, Managing Director and VP Medical and Scientific Affairs, CureDuchenne Ventures  
 Jennifer Farmer, Executive Director, Friedreich's Ataxia Research Alliance  
 Maurice Zauderer, President and Chief Executive Officer, Vaccinex, Inc.  
 PJ Anand, Chief Executive Officer, Alcyone Lifesciences, Inc.  
 Reinhard Gabathuler, Chief Scientist, biOasis Technologies, Inc.  
 Steven Perrin, CEO and CSO, ALS Therapy Development Inst.

**14:15** Neurotrope BioScience, Inc. - [OTCQB:NTRP]

**14:35** Heptares Therapeutics

**14:55** Oryzon Genomics SA - [SM:ORY]

**15:15** **Neuropsychiatry & Pain Management**  
**Chaired:**  
 Maxim Jacobs, Senior Healthcare Analyst, Edison Investment Research  
**Panellists:**  
 Emer Leahy, President and CEO, PsychoGenics Inc.  
 John Kaiser, Chief Business Officer, Cerecor, Inc.  
 Kathryn Gregory, Executive Director, Licensing & Business Development, Purdue Pharma L.P.  
 Paul Thibodeau, Senior Director, Business Development, Teva Pharmaceutical Industries, Ltd.  
 Ronald Notvest, SVP Commercial Planning and Development, Tonix Pharmaceuticals Holding Corp.

**15:15** Alcobra Ltd. - [NASDAQ:ADHD]

**15:35** AgeneBio, Inc.

**16:10** Coffee Break

**Presenting Track D**  
 Moderated by: Sherry Grisewood, Dawson James Securities, Inc.

**Presenting Track E**  
 Moderated by: Keay Nakae, Chardan Capital Markets, LLC

**16:20** Probiodrug AG - [EURONEXT:PBD]

**16:20** Empriver

**16:40** Amaranthus BioScience Holdings, Inc. - [NASDAQ:AMBS]

**16:40** biOasis Technologies, Inc. - [TSX.V:BTI / OTCQB:BIOAF]

**17:00** **Investment Roundtable**  
**Co-Chaired:**  
 Nesson Bermingham, Chief Executive Officer, Intellia Therapeutics, Inc.  
 Steve Dickman, Chief Executive Officer, CBT Advisors  
**Panellists:**  
 Charles Duncan, Managing Director, Senior Research Analyst, Biotechnology, Piper Jaffray  
 Ed Mascioli, Venture Partner, SV Life Science Advisors  
 Eric Schaeffer, Senior Director Neuroscience External Innovation, Johnson & Johnson  
 Jim Ray, Institute Head, Neuroscience, The Neurodegeneration Consortium, MD Anderson  
 Liam Ratcliffe, Managing Director, New Leaf Venture Partners  
 Martin Heidecker, Managing Director, Boehringer Ingelheim Venture USA, Inc.  
 Robert Silverman, Head of Externalized Drug Discovery Partnering, Roche Innovation Center

**18:00** Networking Reception

**19:00** End of the 1st NBPI Forum

Forum Supported by:

